Inhalation systems | Features of available devices | DPI | Novolizer® | Features

Characteristics of the Novolizer® dry powder inhaler

The Novolizer®…


  • is a dry powder inhaler with multiple feedback mechanism to reassure the patient that the inhalation was carried out correctly.
  • is equipped with a dosage stop system releasing the following dose only after the previous dose has been inhaled correctly.
  • has a dose counter which moves after successful inhalation and provides so complance measurement.
  • is avoiding underdosing
  • has a low-to-medium intrinsic resistance. An inspiratory flow rate of at least 35 l/min is necessary to overcome the trigger threshold. However it has been demonstrated that even children aged 4 to 5 years achieved higher peak inspiratory flow rates than required (in average 60 l/min).
  • During an inhalation manoeuvre about 90% of the metered dose is delivered at the mouthpiece with only little variability.

Compared with other devices the Novolizer® has unique features not present in any other DPI.

Drugs approved for use with the Novolizer® include budesonide (Novopulmon®, Budecort®), formoterol (Formatris®, Formotop®), and salbutamol (Ventilastin®, Salbu®).


Asif M, Siddiqui A, Polsker GL. The Novolizer. A multidose dry powder inhaler. 2005. Treatments in Respiratory Medicine, 4 (1): 63-69

Newman SP, Pitcairn GR, Hirst PH, Bacon RE, O'Keefe E, Reiners M, Hermann R. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. 2000. European Respiratory Journal; 16: 178-183

Siddiqui and Plosker Am. J. Drug Deliv. 2006:4 (1); 57-60

Vogelberg C, Kremer HJ, Ellers-Lenz B, Engel M, Maus J, Conrad F, Hermann R. Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer. 2004. Respiratory Medicine; 98: 924-931

Voshaar T. Therapie mit Aerosolen. 2005. Uni-Med: Bremen

Weuthen T, Roeder S, Brand P, M¨llinger B, Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. 2002. Journal of Aerosol Medicine; 15 (3): 297-303

Select language



Do you have questions?
Contact our experts...